Fermín Sánchez-Guijo Martín-rekin lankidetzan egindako argitalpenak (18)

2024

  1. Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells

    Cytotherapy, Vol. 26, Núm. 8, pp. 806-812

2022

  1. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438

2019

  1. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2016

  1. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study

    Bone Marrow Transplantation

2015

  1. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  2. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

  2. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

2011

  1. Effect of vitamin D treatment in chronic GVHD

    Bone Marrow Transplantation

  2. Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs

    Bone Marrow Transplantation

2010

  1. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

2009

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 10, pp. 1331-1336

2008

  1. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 10, pp. 1163-1171

2006

  1. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 9, pp. 936-941

2005

  1. CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Leukemia and Lymphoma, Vol. 46, Núm. 2, pp. 177-183

  2. Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: A comparison with their respective sibling donors

    Biology of Blood and Marrow Transplantation, Vol. 11, Núm. 5, pp. 354-361

  3. Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability

    Experimental Hematology, Vol. 33, Núm. 8, pp. 935-943